BridgeBio Pharma Announces Upcoming Product Launches and Key PDUFA Dates
BridgeBio Pharma (BBIO) has signaled a significant period of commercial expansion, projecting three product launches within the next seven months. The company is transitioning into a new phase for its Transthyretin (TTR) franchise while preparing for critical regulatory milestones. Key upcoming catalysts include a PDUFA date for BBP-418 on November 27 and a PDUFA date for infigratinib on February 4, 2027. Management expressed optimism regarding the portfolio's momentum as the company moves toward these commercialization milestones.
Tickers: $BBIO
Topics: earnings call product launch TTR franchise